• FDA Expands Indication for Soliqua® 100/33 americanpharmaceuticalreview
    March 01, 2019
    The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL.
PharmaSources Customer Service